Integrum AB Class B (DE:6Y1)
FRANKFURT:6Y1
6Y1 Stock Chart & Stats
€0.94
-€0.06(-3.43%)
At close: 4:00 PM EST
€0.94
-€0.06(-3.43%)
Day’s Range― - ―
52-Week Range€0.59 - €3.86
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€17.21M
Enterprise Value€131.46M
Total Cash (Recent Filing)€30.17M
Total Debt (Recent Filing)€3.60M
Price to Earnings (P/E)―
Beta0.23
Next Earnings
Jun 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding26,027,910
10 Day Avg. Volume6
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.64
Price to Sales (P/S)3.20
P/FCF Ratio-5.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Product NicheIntegrum operates in a narrow, high-barrier medical niche—osseointegration implants for amputees—which relies on specialized clinical centers. This focused product line and clinical orientation create durable differentiation and patient-specific demand that supports long-term revenue visibility and clinical adoption cycles.
Low Financial LeverageA very low debt load reduces near-term solvency risk and preserves financial flexibility. For a cash-consuming med-tech, low leverage lowers refinancing pressure, supports investment in clinical rollout and R&D, and provides runway to execute commercialization without immediate debt-servicing constraints.
Prior Demonstrated ProfitabilityHistorical profitability indicates the business model can generate positive margins when scale or operating conditions align. This suggests underlying gross economics can support returns, implying that with better revenue traction or cost control the company can return to sustainable profitability over a multi-quarter horizon.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow is a structural pressure that increases funding risk and may necessitate dilutive equity raises or constrained investment. For a small med-tech, ongoing cash burn limits ability to scale commercialization and prolongs the timeline to achieve self-sustaining operations.
Earnings VolatilityLarge swings from prior profitability to recent sizable losses show unstable earnings and weak capital efficiency. This volatility complicates planning for commercialization and capital allocation, increasing execution risk and making margins and return metrics uncertain over the medium term.
Weak/flat Revenue TrendStagnant to slightly declining revenue constrains operating leverage and makes it harder to absorb fixed R&D and sales costs. For a niche device company reliant on clinical adoption, weak top-line traction prolongs cash burn and delays achieving scale-driven margin improvement and consistent profitability.
Integrum AB Class B News
6Y1 FAQ
What was Integrum AB Class B’s price range in the past 12 months?
Integrum AB Class B lowest stock price was €0.59 and its highest was €3.86 in the past 12 months.
What is Integrum AB Class B’s market cap?
Integrum AB Class B’s market cap is €17.21M.
When is Integrum AB Class B’s upcoming earnings report date?
Integrum AB Class B’s upcoming earnings report date is Jun 05, 2026 which is in 56 days.
How were Integrum AB Class B’s earnings last quarter?
Integrum AB Class B released its earnings results on Mar 02, 2026. The company reported -€0.043 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.043.
Is Integrum AB Class B overvalued?
According to Wall Street analysts Integrum AB Class B’s price is currently Overvalued.
Does Integrum AB Class B pay dividends?
Integrum AB Class B does not currently pay dividends.
What is Integrum AB Class B’s EPS estimate?
Integrum AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Integrum AB Class B have?
Integrum AB Class B has 26,027,910 shares outstanding.
What happened to Integrum AB Class B’s price movement after its last earnings report?
Integrum AB Class B reported an EPS of -€0.043 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.91%.
Which hedge fund is a major shareholder of Integrum AB Class B?
Currently, no hedge funds are holding shares in DE:6Y1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Integrum AB Class B
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. The company also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide. The company was founded in 1962 and is headquartered in Mölndal, Sweden.